Abstract
Prostatic carcinogenesis proceeds via the acquisition of both genetic and epigenetic alterations. The epigenetic changes, principally in DNA methylation patterns and in chromatin structure, are equivalent to genetic changes, and often lead to defects in the functions of critical genes, which contribute to malignant cell behaviors. Epigenetic alterations also tend to appear at the earliest stages of prostate cancer development. As such, analysis of epigenetic genome changes has not only led to a new understanding of how prostate cancers likely arise, but has also provided new translational research opportunities, both for molecular biomarkers likely to aid in prostate cancer detection and diagnosis and for strategies to prevent and treat the disease.
Key Word
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Hanahan, D. and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57–70.
Herman, J. G. and Baylin, S. B. (2003). Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349, 2042–2054.
Bird, A. P. (1986). CpG-rich islands and the function of DNA methylation. Nature 321, 209–213.
Feinberg, A. P. and Tycko, B. (2004). The history of cancer epigenetics. Nat. Rev. Cancer 4, 143–153.
Gaudet, F., Hodgson, J. G., Eden, A., et al. (2003). Induction of tumors in mice by genomic hypomethylation. Science 300, 489–492.
Eden, A., Gaudet, F., Waghmare, A., and Jaenisch, R. (2003). Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300, 455.
Vertino, P. M., Yen, R. W., Gao, J., and Baylin, S. B. (1996). De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)-methyltransferase. Mol. Cell Biol. 16, 4555–4565.
Di Croce, L., Raker, V. A., Corsaro, M., et al. (2002). Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295, 1079–1082.
Kawasaki, H. and Taira, K. (2004). Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature 431, 211–217.
Morris, K. V., Chan, S. W., Jacobsen, S. E., and Looney, D. J. (2004). Small interfering RNA-induced transcriptional gene silencing in human cells. Science 305, 1289–1292.
Holst, C. R., Nuovo, G. J., Esteller, M., et al. (2003). Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res. 63, 1596–1601.
David, G. L., Yegnasubramanian, S., Kumar, A., et al. (2004). MDR1 promoter hypermethylation in MCF-7 human breast cancer cells: changes in chromatin structure induced by treatment with 5-Aza-cytidine. Cancer Biol. Ther. 3, 540–548.
Myohanen, S. K., Baylin, S. B., and Herman, J. G. (1998). Hypermethylation can selectively silence individual p16ink4A alleles in neoplasia. Cancer Res. 58, 591–593.
Jeltsch, A. (2002). Beyond Watson and Crick: DNA methylation and molecular enzymology of DNA methyltransferases. Chembiochem. 3, 274–293.
Leonhardt, H., Page, A. W., Weier, H. U., and Bestor, T. H. (1992). A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei. Cell 71, 865–873.
Okano, M., Bell, D. W., Haber, D. A., and Li, E. (1999). DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99, 247–257.
Rhee, I., Jair, K. W., Yen, R. W., et al. (2000). CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 404, 1003–1007.
Rhee, I., Bachman, K. E., Park, B. H., et al. (2002). DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416, 552–556.
Graff, J. R., Herman, J. G., Myohanen, S., Baylin, S. B., and Vertino, P. M. (1997). Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J. Biol. Chem. 272, 22,322–22,329.
Feltus, F. A., Lee, E. K., Costello, J. F., Plass, C., and Vertino, P. M. (2003). Predicting aberrant CpG island methylation. Proc. Natl. Acad. Sci. USA 100, 12,253–12,258.
Bakin, A. V. and Curran, T. (1999). Role of DNA 5-methylcytosine transferase in cell transformation by fos. Science 283, 387–390.
Laird, P. W., Jackson-Grusby, L., Fazeli, A., et al. (1995). Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81, 197–205.
Eads, C. A., Nickel, A. E., and Laird, P. W. (2002). Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) Dnmt1-hypomorphic Mice. Cancer Res 62, 1296–1299.
Belinsky, S. A., Klinge, D. M., Stidley, C. A., et al. (2003). Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res. 63, 7089–7093.
Eads, C. A., Danenberg, K. D., Kawakami, K., Saltz, L. B., Danenberg, P. V., and Laird, P. W. (1999). CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res. 59, 2302–2306.
Agoston, A. T., Argani, P., Yegnasubramanian, S., et al. (2005). Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J. Biol. Chem. 280, 18,302–18,310.
De Marzo, A. M., Marchi, V. L., Yang, E. S., Veeraswamy, R., Lin, X., and Nelson, W. G. (1999). Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis. Cancer Res. 59, 3855–3860.
Lee, W. H., Morton, R. A., Epstein, J. I., et al. (1994). Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA 91, 11,733–11,737.
Nelson, W. G., De Marzo, A. M., and Isaacs, W. B. (2003). Prostate cancer. N. Engl. J. Med. 349, 366–381.
Nelson, C. P., Kidd, L. C., Sauvageot, J., et al. (2001). Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[ 4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res. 61, 103–109.
Lin, X., Tascilar, M., Lee, W. H., et al. (2001). GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am. J. Pathol. 159, 1815–1826.
Henderson, C. J., Smith, A. G., Ure, J., Brown, K., Bacon, E. J., and Wolf, C. R. (1998). Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. Proc. Natl. Acad. Sci. USA 95, 5275–5280.
Millar, D. S., Paul, C. L., Molloy, P. L., and Clark, S. J. (2000). A distinct sequence (ATAAA)n separates methylated and unmethylated domains at the 5′-end of the GSTP1 CpG island. J. Biol. Chem. 275, 24,893–24,899.
De Marzo, A. M., Marchi, V. L., Epstein, J. I., and Nelson, W. G. (1999). Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am. J. Pathol. 155, 1985–1992.
DeMarzo, A. M., Nelson, W. G., Isaacs, W. B., and Epstein, J. I. (2003). Pathological and molecular aspects of prostate cancer. Lancet 361, 955–964.
Nakayama, M., Bennett, C. J., Hicks, J. L., et al. (2003). Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am. J. Pathol. 163, 923–933.
Brooks, J. D., Weinstein, M., Lin, X., et al. (1998). CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia. Cancer Epidemiol. Biomarkers Prev. 7, 531–536.
DeWeese, T. L. and Nelson, W. G. (2003). Inadequate “caretaker” gene function and human cancer development. Methods Mol. Biol. 222, 249–268.
Hmadcha, A., Bedoya, F. J., Sobrino, F., and Pintado, E. (1999). Methylation-dependent gene silencing induced by interleukin 1beta via nitric oxide production. J. Exp. Med. 190, 1595–1604.
Bastian, P. J., Yegnasubramanian, S., Palapattu, G. S., et al. (2004). Molecular biomarker in prostate cancer: the role of CpG island hypermethylation. Eur. Urol. 46, 698–708.
Yegnasubramanian, S., Kowalski, J., Gonzalgo, M. L., et al. (2004). Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 64, 1975–1986.
Bedford, M. T. and van Helden, P. D. (1987). Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res. 47, 5274–5276.
Santourlidis, S., Florl, A., Ackermann, R., Wirtz, H. C., and Schulz, W. A. (1999). High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate 39, 166–174.
Florl, A. R., Steinhoff, C., Muller, M., et al. (2004). Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br. J. Cancer 91, 985–994.
Schulz, W. A., Elo, J. P., Florl, A. R., et al. (2002). Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer 35, 58–65.
Soh, S., Kattan, M. W., Berkman, S., Wheeler, T. M., and Scardino, P. T. (1997). Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J. Urol. 157, 2212–2218.
Thompson, I. M., Pauler, D. K., Goodman, P. J., et al. (2004). Prevalence of prostate cancer among men with a prostatespecific antigen level < or =4.0 ng per milliliter. N. Engl. J. Med. 350, 2239–2246.
Thompson, I. M., Goodman, P. J., Tangen, C. M., et al. (2003). The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215–224.
Makhlouf, A. A., Krupski, T. L., Kunkle, D., and Theodorescu, D. (2004). The effect of sampling more cores on the predictive accuracy of pathological grade and tumour distribution in the prostate biopsy. BJU Int. 93, 271–274.
de la Taille, A., Antiphon, P., Salomon, L., et al. (2003). Prospective evaluation of a 21-sample needle biopsy procedure designed to improve the prostate cancer detection rate. Urology 61, 1181–1186.
Sidransky, D. (2002). Emerging molecular markers of cancer. Nat. Rev. Cancer 2, 210–219.
Laird, P. W. (2003). The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3, 253–266.
Lee, W. H., Isaacs, W. B., Bova, G. S., and Nelson, W. G. (1997). CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol. Biomarkers Prev. 6, 443–450.
Clark, S. J., Harrison, J., Paul, C. L., and Frommer, M. (1994). High sensitivity mapping of methylated cytosines. Nucleic Acids Res. 22, 2990–2997.
Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. (1996). Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93, 9821–9826.
Harden, S. V., Sanderson, H., Goodman, S. N., et al. (2003). Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J. Natl. Cancer Inst. 95, 1634–1637.
Gonzalgo, M. L., Nakayama, M., Lee, S. M., De Marzo, A. M., and Nelson, W. G. (2004). Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. Urology 63, 414–418.
Goessl, C., Muller, M., Heicappell, R., Krause, H., and Miller, K. (2001). DNA-based detection of prostate cancer in blood, urine, and ejaculates. Ann. NY Acad. Sci. 945, 51–58.
Gonzalgo, M. L., Pavlovich, C. P., Lee, S. M., and Nelson, W. G. (2003). Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin. Cancer Res. 9, 2673–2677.
Jeronimo, C., Henrique, R., Hoque, M. O., et al. (2004). Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin. Cancer Res. 10, 4010–4014.
Liu, L., Yoon, J. H., Dammann, R., and Pfeifer, G. P. (2002). Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 21, 6835–6840.
Zhang, J., Liu, L., and Pfeifer, G. P. (2004). Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene. Oncogene 23, 2241–2249.
Zhu, X., Leav, I., Leung, Y. K., et al. (2004). Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am. J. Pathol. 164, 2003–2012.
Bastian, P. J., Palapattu, G. S., Lin, X., et al. (2005). Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin. Cancer Res. 11, 4037–4043.
Kaminskas, E., Farrell, A., Abraham, S., et al. (2005). Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin. Cancer Res. 11, 3604–3608.
Jones, P. A. and Taylor, S. M. (1980). Cellular differentiation, cytidine analogs and DNA methylation. Cell 20, 85–93.
Cheng, J. C., Matsen, C. B., Gonzales, F. A., et al. (2003). Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl. Cancer Inst. 95, 399–409.
Lin, X., Asgari, K., Putzi, M. J., et al. (2001). Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Res. 61, 8611–8616.
Segura-Pacheco, B., Trejo-Becerril, C., Perez-Cardenas, E., et al. (2003). Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin. Cancer Res. 9, 1596–1603.
Kelly, W. K., Richon, V. M., O’Connor, O., et al. (2003). Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9, 3578–3588.
Carducci, M. A., Gilbert, J., Bowling, M. K., et al. (2001). A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res. 7, 3047–3055.
Carducci, M. A., Nelson, J. B., Chan-Tack, K. M., et al. (1996). Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin. Cancer Res. 2, 379–387.
Gilbert, J., Baker, S. D., Bowling, M. K., et al. (2001). A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res. 7, 2292–2300.
Santini, V., Kantarjian, H. M., and Issa, J. P. (2001). Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann. Intern. Med. 134, 573–586.
Thibault, A., Figg, W. D., Bergan, R. C., et al. (1998). A phase II study of 5-aza-2’deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori 84, 87–89.
Jackson-Grusby, L., Laird, P. W., Magge, S. N., Moeller, B. J., and Jaenisch, R. (1997). Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc. Natl. Acad. Sci. USA 94, 4681–4685.
Scheinbart, L. S., Johnson, M. A., Gross, L. A., Edelstein, S. R., and Richardson, B. C. (1991). Procainamide inhibits DNA methyltransferase in a human T cell line. J. Rheumatol. 18, 530–534.
Cornacchia, E., Golbus, J., Maybaum, J., Strahler, J., Hanash, S., and Richardson, B. (1988). Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J. Immunol. 140, 2197–2200.
Lee, B. H., Yegnasubramanian, S., and Nelson, W. G. (2005). Procainamide is a specific inhibitor of DNA methyltransferase 1. J. Biol. Chem. 280, 40,749–40,756
Quddus, J., Johnson, K. J., Gavalchin, J., et al. (1993). Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J. Clin. Invest. 92, 38–53.
Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G., and Baylin, S. B. (1999). Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21, 103–107.
Jones, P. L., Veenstra, G. J., Wade, P. A., et al. (1998). Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 19, 187–191.
Feng, Q. and Zhang, Y. (2001). The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev. 15, 827–832.
Bakker, J., Lin, X., and Nelson, W. G. (2002). Methyl-CpG binding domain protein 2 represses transcription from hypermethylated pi-class glutathione S-transferase gene promoters in hepatocellular carcinoma cells. J. Biol. Chem. 277, 22,573–22,580.
Lin, X. and Nelson, W. G. (2003). Methyl-CpG-binding domain protein-2 mediates transcriptional repression associated with hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells. Cancer Res. 63, 498–504.
Hendrich, B., Guy, J., Ramsahoye, B., Wilson, V. A., and Bird, A. (2001). Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev. 15, 710–723.
Sansom, O. J., Berger, J., Bishop, S. M., Hendrich, B., Bird, A., and Clarke, A. R. (2003). Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat. Genet. 34, 145–147.
Sansom, O. J., Bishop, S. M., Bird, A., and Clarke, A. R. (2005). MBD2 deficiency does not accelerate p53 mediated lymphomagenesis. Oncogene 24, 2430–2432.
Campbell, P. M., Bovenzi, V., and Szyf, M. (2004). Methylated DNA-binding protein 2 antisense inhibitors suppress tumourigenesis of human cancer cell lines in vitro and in vivo. Carcinogenesis 25, 499–507.
Slack, A., Bovenzi, V., Bigey, P., et al. (2002). Antisense MBD2 gene therapy inhibits tumorigenesis. J. Gene Med. 4, 381–389.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Nelson, W.G., Yegnasubramanian, S., Bastian, P.J., Nakayama, M., De Marzo, A.M. (2007). Somatic DNA Methylation Changes and Prostatic Carcinogenesis. In: Chung, L.W.K., Isaacs, W.B., Simons, J.W. (eds) Prostate Cancer. Contemporary Cancer Research. Humana Press. https://doi.org/10.1007/978-1-59745-224-3_17
Download citation
DOI: https://doi.org/10.1007/978-1-59745-224-3_17
Publisher Name: Humana Press
Print ISBN: 978-1-58829-696-2
Online ISBN: 978-1-59745-224-3
eBook Packages: MedicineMedicine (R0)